- Home
- FISI vs SIGA Comparison
FISI vs SIGA Comparison
Compare FISI & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FISI | SIGA |
|---|---|---|
| Founded | 1817 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 615.8M | 421.8M |
| IPO Year | 1999 | 1997 |
Fundamental Metrics
Financial Performance| Metric | FISI | SIGA |
|---|---|---|
| Price | $32.72 | $6.45 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $33.33 | N/A |
| AVG Volume (30 Days) | 105.8K | ★ 368.9K |
| Earning Date | 01-29-2026 | 11-06-2025 |
| Dividend Yield | 3.80% | ★ 9.29% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | $116,735,000.00 | ★ $172,249,641.00 |
| Revenue This Year | $124.17 | N/A |
| Revenue Next Year | $6.77 | $132.36 |
| P/E Ratio | ★ N/A | $6.27 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.97 | $4.95 |
| 52 Week High | $32.99 | $9.62 |
Technical Indicators
Market Signals| Indicator | FISI | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 76.08 | 48.09 |
| Support Level | $30.83 | $6.13 |
| Resistance Level | $31.42 | $6.55 |
| Average True Range (ATR) | 0.58 | 0.21 |
| MACD | 0.19 | 0.14 |
| Stochastic Oscillator | 96.17 | 86.81 |
Price Performance
Historical ComparisonAbout FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.